View all AI CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps highlight key elements of the Advances in™ Targeted Therapies: The Emerging Role of PI3K Inhibitors in the Treatment of Hematologic Malignancies.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Advances in™ Targeted Therapies: The Emerging Role of PI3K Inhibitors in the Treatment of Hematologic Malignancies


Release Date: November 16, 2016
Expiration Date: November 16, 2017
Media: Internet - based

Activity Overview 

This activity will focus on treating hematologic malignancies through inhibition of the PI3K family of enzymes and will include expert video interviews, accompanied by a series of clinical vignettes, that allow participants to apply the information presented in the interviews.

CME/CE Activity Table of Contents

  • Pretest
  • Rationale for Using Isoform-Specific PI3K Inhibitors
  • Isoform-Specific PI3K Inhibitors in Heavily Pretreated Patients and Treatment-Naïve Patients
  • Recent Clinical Data on Novel Isoform-Specific PI3K Inhibitors
  • Identification of Patients Likely to Achieve Greatest Clinical Benefit,
    and Managing Toxicities Associated With PI3K Inhibitors
  • Closing Remarks
  • Posttest
 

 

Instructions For This Activity & Receiving Credit

  • Once you begin the activity, please answer the demographic questions. This will allow you to proceed to the activity.
  • This activity contains one or more interactive questions. You may move forward through the activity; however, you may not go back to change answers or review content until you finish the activity.
  • At the end of the activity, an “Educational Content” link will be available for you to download content in PDF format for your reference.
  • If you close the Web browser after you complete the activity, the Educational Content link will disappear and you will need to review the activity in its entirety to once again access the link.
  • In order to receive a CME certificate, participants must complete the activity.
  • Click on the “Request Credits” link at the end of the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity will focus on treating hematologic malignancies through inhibition of the PI3K family of enzymes and will include expert video interviews, accompanied by a series of clinical vignettes, that allow participants to apply the information presented in the interviews.

Educational Objectives

At the conclusion of this activity, you should be better prepared to: 
  • Describe the mechanism of action of novel PI3K inhibitors
  • Discuss recent clinical trial data for PI3K inhibitors in patients with hematologic malignancies
  • Explain the current and emerging roles for PI3K inhibition strategies and apply them to care for appropriate patients with hematologic malignancies
  • Apply knowledge of predicable adverse event profiles to proactively counsel and manage treatment-related toxicities in patients with hematologic malignancies


Faculty, Staff, and Planners' Disclosures

Faculty

Susan O’Brien, MD
Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Medical Director
Sue and Ralph Stern Center for Cancer Clinical Trials & Research
Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, Irvine
Irvine, CA
Disclosure: Grant/Research Support: Acerta, TG Therapeutics, Regeneron, Gilead, Pharmacyclics, ProNAi; Consultant: Amgen, Celgene, GSK, Janssen.
 

Ian W. Flinn, MD, PhD
Director
Blood Cancer Research Program
Principal Investigator
Sarah Cannon Research Institute
Nashville, TN
Disclosure: Grant/Research Support: Acerta, BeiGene, Celgene, Constellation, Curis, Forty Seven, Genentech, Gilead, ImmunoGen, Incyte, Infinity, Janssen, KITE, Novartis, Portola, Seattle Genetics, Takeda, TG Therapeutics, Trillium.

The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
 

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By